Literature DB >> 24147599

Effects of long-term hypoxia and pro-survival cocktail in bone marrow-derived stromal cell survival.

Saejeong Kim1, Aneeka Chaudhry, Inae Lee, Joseph A Frank.   

Abstract

The goal of this study was to determine whether a pro-survival cocktail (PSC, consisting of IGF-1, Bcl-XL, and Caspase-I Inhibitor) and long-term hypoxia (LTH) enhance survival and functional properties of bone marrow-derived stromal stem cells (BMSCs), in response to stress conditions. PSC-treated cells retained BMSC surface markers and protected cells from apoptosis under serum starvation and ischemic (1% O2 and 100 μM H2O2) conditions. LTH promoted osteogenesis, while suppressing adipogenesis. LTH alone did not result in an improvement in the apoptosis rate; however, PSC conferred significant protection regardless of the oxygenation status. One of the possible mechanisms of PSC protection was due to the elevated phospho-AKT in treated groups. PSC treatment or LTH did not alter migration toward stem cell-derived factor-1 alpha (SDF-1α) or fetal bovine serum, nor did they enhance cell motility during wound healing. There was no difference in the secreted cytokine profiles of BMSCs treated with PSC after stress when grown in normoxic or LTH. However, LTH did upregulate the vascular endothelial growth factor, hepatocyte growth factor, and SDF-1α, while it downregulated other anti- and proinflammatory cytokines and chemokines. We also observed a high degree of interdonor BMSC variability in response to pretreatment with PSC and LTH, confounding the functional results, underscoring the observation that not all donor-derived BMSCs will respond similarly.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24147599      PMCID: PMC3928716          DOI: 10.1089/scd.2013.0297

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  41 in total

1.  Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect.

Authors:  Uwe M Fischer; Matthew T Harting; Fernando Jimenez; Werner O Monzon-Posadas; Hasen Xue; Sean I Savitz; Glen A Laine; Charles S Cox
Journal:  Stem Cells Dev       Date:  2009-06       Impact factor: 3.272

Review 2.  Mechanisms involved in the therapeutic properties of mesenchymal stem cells.

Authors:  Lindolfo da Silva Meirelles; Aparecida Maria Fontes; Dimas Tadeu Covas; Arnold I Caplan
Journal:  Cytokine Growth Factor Rev       Date:  2009-11-18       Impact factor: 7.638

3.  Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression.

Authors:  Sheik Wisel; Mahmood Khan; M Lakshmi Kuppusamy; I Krishna Mohan; Simi M Chacko; Brian K Rivera; Benjamin C Sun; Kálmán Hideg; Periannan Kuppusamy
Journal:  J Pharmacol Exp Ther       Date:  2009-02-13       Impact factor: 4.030

4.  VEGF improves survival of mesenchymal stem cells in infarcted hearts.

Authors:  Jennifer Pons; Yu Huang; Janice Arakawa-Hoyt; Daniel Washko; Junya Takagawa; Jianqin Ye; William Grossman; Hua Su
Journal:  Biochem Biophys Res Commun       Date:  2008-09-18       Impact factor: 3.575

5.  Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium.

Authors:  Zeeshan Pasha; Yigang Wang; Riazuddin Sheikh; Dongsheng Zhang; Tiemin Zhao; Muhammad Ashraf
Journal:  Cardiovasc Res       Date:  2007-09-22       Impact factor: 10.787

6.  Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts.

Authors:  Michael A Laflamme; Kent Y Chen; Anna V Naumova; Veronica Muskheli; James A Fugate; Sarah K Dupras; Hans Reinecke; Chunhui Xu; Mohammad Hassanipour; Shailaja Police; Chris O'Sullivan; Lila Collins; Yinhong Chen; Elina Minami; Edward A Gill; Shuichi Ueno; Chun Yuan; Joseph Gold; Charles E Murry
Journal:  Nat Biotechnol       Date:  2007-08-26       Impact factor: 54.908

7.  Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells.

Authors:  Ivana Rosová; Mo Dao; Ben Capoccia; Daniel Link; Jan A Nolta
Journal:  Stem Cells       Date:  2008-05-29       Impact factor: 6.277

Review 8.  Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke.

Authors:  Permphan Dharmasaroja
Journal:  J Clin Neurosci       Date:  2008-11-18       Impact factor: 1.961

Review 9.  Progenitor cell therapy for heart disease.

Authors:  Christine Gonzales; Thierry Pedrazzini
Journal:  Exp Cell Res       Date:  2009-09-10       Impact factor: 3.905

10.  Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2.

Authors:  Ha Won Kim; Husnain K Haider; Shujia Jiang; Muhammad Ashraf
Journal:  J Biol Chem       Date:  2009-08-31       Impact factor: 5.157

View more
  7 in total

1.  Cyclooxygenase-2 or tumor necrosis factor-α inhibitors attenuate the mechanotransductive effects of pulsed focused ultrasound to suppress mesenchymal stromal cell homing to healthy and dystrophic muscle.

Authors:  Pamela A Tebebi; Scott R Burks; Saejeong J Kim; Rashida A Williams; Ben A Nguyen; Priyanka Venkatesh; Victor Frenkel; Joseph A Frank
Journal:  Stem Cells       Date:  2015-04       Impact factor: 6.277

2.  Failure of intravenous or intracardiac delivery of mesenchymal stromal cells to improve outcomes after focal traumatic brain injury in the female rat.

Authors:  L Christine Turtzo; Matthew D Budde; Dana D Dean; Eric M Gold; Bobbi K Lewis; Lindsay Janes; Jacob Lescher; Tiziana Coppola; Angela Yarnell; Neil E Grunberg; Joseph A Frank
Journal:  PLoS One       Date:  2015-05-06       Impact factor: 3.240

3.  In situ normoxia enhances survival and proliferation rate of human adipose tissue-derived stromal cells without increasing the risk of tumourigenesis.

Authors:  Jane Ru Choi; Belinda Pingguan-Murphy; Wan Abu Bakar Wan Abas; Kar Wey Yong; Chi Tat Poon; Mat Adenan Noor Azmi; Siti Zawiah Omar; Kien Hui Chua; Feng Xu; Wan Kamarul Zaman Wan Safwani
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

4.  Transplantation of Hypoxic-Preconditioned Bone Mesenchymal Stem Cells Retards Intervertebral Disc Degeneration via Enhancing Implanted Cell Survival and Migration in Rats.

Authors:  Weiheng Wang; Yang Wang; Guoying Deng; Jun Ma; Xiaodong Huang; Jiangming Yu; Yanhai Xi; Xiaojian Ye
Journal:  Stem Cells Int       Date:  2018-02-14       Impact factor: 5.443

5.  A new method of wound treatment: targeted therapy of skin wounds with reactive oxygen species-responsive nanoparticles containing SDF-1α.

Authors:  Tao Tang; Hao Jiang; Yuan Yu; Fang He; Shi-zhao Ji; Ying-ying Liu; Zhong-shan Wang; Shi-chu Xiao; Cui Tang; Guang-Yi Wang; Zhao-Fan Xia
Journal:  Int J Nanomedicine       Date:  2015-10-19

6.  Preconditioning of bone marrow mesenchymal stem cells with hydrogen sulfide improves their therapeutic potential.

Authors:  Qun Zhang; Song Liu; Tong Li; Lin Yuan; Hansen Liu; Xueer Wang; Fuwu Wang; Shuanglian Wang; Aijun Hao; Dexiang Liu; Zhen Wang
Journal:  Oncotarget       Date:  2016-09-06

7.  MR-guided pulsed focused ultrasound improves mesenchymal stromal cell homing to the myocardium.

Authors:  Kee W Jang; Tsang-Wei Tu; Robert B Rosenblatt; Scott R Burks; Joseph A Frank
Journal:  J Cell Mol Med       Date:  2020-10-17       Impact factor: 5.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.